Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China: Analysis of the results from the Chinese National Stroke Registry (CNSR)

Stroke

Volumn 42, Issue 6, 2011, Pages 1658-1664

  Wang, Yilong ^a   Liao, Xiaoling ^a   Zhao, Xingquan ^a   Wang, David Z ^b   Wang, Chunxue ^a   Nguyen Huynh, Mai N ^c   Zhou, Yong ^a   Liu, Liping ^a   Wang, Xianwei ^a   Liu, Gaifen ^a   Li, Hao ^a   Wang, Yongjun ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF ILLINOIS   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

registries; stroke; thrombolytic therapy

Indexed keywords

ALTEPLASE;

ACUTE ISCHEMIC STROKE; AGED; ARTICLE; BRAIN ISCHEMIA; CHINA; CONTROLLED STUDY; DEVELOPED COUNTRY; DISEASE REGISTRY; DRUG USE; EMERGENCY CARE; EMERGENCY WARD; FEMALE; FIBRINOLYTIC THERAPY; GOVERNMENT; HUMAN; INCOME; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PRIORITY JOURNAL; URBAN AREA;

ADOLESCENT; ADULT; AGED; BRAIN ISCHEMIA; CHINA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; REGISTRIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958295232     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.604249     Document Type: Article

References (20)

1. Johnston SC, Mendis S, Mathers CD. Global variation in stroke burden and mortality: estimates from monitoring, surveillance, and modelling. Lancet Neurol. 2009;8:345-354.
2. Wang YL, Wu D, Liao X, Zhang W, Zhao X, Wang YJ. Burden of stroke in China. Int J Stroke. 2007;2:211-213. (Pubitemid 47103698)
3. Chen Z. The mortality and death cause of national sample areas. In: Chen Z, ed. The Third National Survey on the Cause of Death, 1st Ed. Beijing: Peking Union Medical University Press;2008:14-15.
4. Liu M, Wu B, Wang W-Z, Lee L-M, Zhang S-H, Kong L-Z. Stroke in China: epidemiology, prevention, and management strategies. Lancet Neurol. 2007;6:456-464. (Pubitemid 46551849)
5. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.
6. Reeves MJ, Arora S, Broderick JP, Frankel M, Heinrich JP, Hickenbottom S, Karp H, LaBresh KA, Malarcher A, Mensah G, Moomaw CJ, Schwamm L, Weiss P; Paul Coverdell Prototype Registries Writing Group. Acute stroke care in the US: results from 4 pilot prototypes of the Paul Coverdell national acute stroke registry. Stroke. 2005;36:1232-1240. (Pubitemid 40798745)
7. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, Malkoff M, Alexandrov AV. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol. 2001;58:2009-2013. (Pubitemid 33143979)
8. Birbeck GL, Cui X, Zingmond DS, Vickrey BG. IV-tPA use in California: resources and recipients. Cerebrovasc Dis. 2004;17:341-343.
9. Barber PA, Zhang J, Demchuk AM, Hill MD, Buchan AM. Why are stroke patients excluded from tPA therapy? An analysis of patient eligibility. Neurology. 2001;56:1015-1020. (Pubitemid 32336306)
10. Kleindorfer D, Kissela B, Schneider A, Woo D, Khoury J, Miller R, Alwell K, Gebel J, Szaflarski J, Pancioli A, Jauch E, Moomaw C, Shukla R, Broderick JP; Neuroscience Institute. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: a population-based study. Stroke. 2004;35:e27-e29.
11. Statistical Information Center Investigator Group. China Health Statistical Yearbook 2008. Ministry of Health of the People's Republic of China. Available at: www.moh.gov.cn/publicfiles/business/htmlfiles/zwgkzt/ptjnj/ 200809/37759.htm. Accessed April 10, 2007.
12. Deng YZ, Reeves MJ, Jacobs BS, Birbeck GL, Kothari RU, Hickenbottom SL, Mullard AJ, Wehner S, Maddox K, Majid A; for the Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology. 2006;66:306-312. (Pubitemid 43739928)
13. Kapral MK, Silver FL, Richards JA, Lindsay MP, Fang J, Shi S, Hill MD, Phillips SJ, Robertson A, Tu JV. RCSN Progress Reports. Canadian Stroke Network. Available at: www.rcsn.org/ReportPublications.aspx. Accessed July 12, 2010.
14. Hills NK, Johnston SC. Duration of hospital participation in a nationwide stroke registry is associated with improved quality of care. BMC Neurol. 2006;6:20.
15. Leys D, Ringelstein EB, Kaste M, Hacke W; for the Executive Committee of the European Stroke Initiative. Facilities available in European hospitals treating stroke patients. Stroke. 2007;38:2985-2991. (Pubitemid 350035694)
16. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, Hennerici MG, Markku Kaste M, Kuelkens S, Larrue V, Lees KR, Roine RO, Soinne L, Toni D, Vanhooren G; for the SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282. (Pubitemid 46138121)
17. Jorgensen H, Nakayama H, Reith J, Raaschou H, Olsen T. Factors delaying hospital admission in acute stroke: the Copenhagen Stroke Study. Neurology. 1996;47:383-387. (Pubitemid 26324031)
18. Mishra NK, Lyden P, Grotta JC, Lee KR; for the VISTA Collaborators. Thrombolysis is associated with consistent functional improvement across baseline stroke severity: a comparison of outcomes in patients from the Virtual International Stroke Trials Archive (VISTA). Stroke. 2010;41:2612-2617.
19. Yamaguchi T, Mori E, Minematsu K, Nakagawara J, Hashi K, Saito I, Shinohara Y; for the Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset. Japan Alteplase Clinical Trial (J-ACT). Stroke. 2006;37:1810-1815. (Pubitemid 44297734)
20. Zhou X-Y, Wang S-S, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J Clin Neurosci. 2010;17:988-992.